M. Perry

J. Crawford, M. Perry, C. Belani, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Corticosteroids in advanced cancer.

M. Perry, J. Wooldridge, C. Anderson, 2001, Oncology.

Hemoglobin Columbia Missouri or α2[88 (F9) Ala→Val]β2: A New High-Oxygen-Affinity Hemoglobin That Causes Erythrocytosis

V. Proud, M. Perry, Richard T. Jones, 1991 .

Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.

G. Reddy, V. Jain, M. Perry, 2004, Clinical lung cancer.

Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study

W. Wood, M. Perry, C. Kardinal, 1983, Breast Cancer Research and Treatment.

Chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil compared to chemotherapy plus hormonal therapy with tamoxifen in the treatment of advanced breast cancer: an interim analysis.

W. Wood, M. Perry, C. Kardinal, 1983, Journal of steroid biochemistry.

A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.

A. Gajra, N. Ready, M. Perry, 2007, Lung cancer.

O-254 Prevention of anemia with once weekly (QW) epoetin alfa in patients with non-small-cell lung cancer (NSCLC)

J. Crawford, M. Perry, C. Belani, 2003 .

Chemotherapy of cervical carcinoma.

M. Perry, J. Yarbro, M. Muscato, 1982, Seminars in oncology.

Massive phrenic perineurioma mimicking an unresectable cardiac tumor.

T. Demmy, M. Perry, J. Curtis, 1995, The Annals of thoracic surgery.

Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxel

J. R. Pereira, R. Gralla, M. Perry, 2004 .

Induction treatment for resectable non-small-cell lung cancer.

N. Choi, F. Shepherd, J. Deslauriers, 1997, Lung cancer.

Non-Hodgkin's lymphoma of the synovium simulating rheumatoid arthritis.

H. Dorfman, M. Perry, R. Oxenhandler, 1987, Arthritis and rheumatism.

Book Review Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician Edited by Frank C. Detterbeck, Mark A. Socinski, M. Patricia Rivera, and Julian G. Rosenman. 480 pp., illustrated. Philadelphia, W.B. Saunders, 2001. $135. 0-7216-9192-7

M. Perry, 2001 .

Metastatic cervical adenocarcinoma from unknown primary tumor. Treatment dilemma.

M. Perry, W. E. Davis, J. Templer, 1981, Archives of otolaryngology.

2 Randomized prospective comparison of adjuvant mediastinal radiation (RT) with or without concurrent chemotherapy with cisplatin and etoposide (PE) for patients with completely resected 51-3N1-2M0 non-small cell lung cancer (NSCLC): US

R. Komaki, S. Adak, R. Livingston, 1999 .

High incidence of hypersensitivity reactions to cetuximab infusions in mid-Missouri: Association with prior history of atopy

M. Perry, S. Haddadin, A. Gill, 2008 .

Osteogenic sarcoma following Hodgkin's disease

M. Perry, N. Hakami, D. Niebrugge, 1981, Cancer.

Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer

W. Wood, M. Perry, A. Forastiere, 2004, Cancer Chemotherapy and Pharmacology.

Toxicity of chemotherapy

M. Perry, J. Yarbro, 1984 .

Familial erythrophagocytic lymphohistiocytosis. report of two cases and clinicopathologic review

M. Perry, G. Gilchrist, E. O. Burgert, 1976, Cancer.

Malignant neoplasms in the families of patients with ataxia-telangiectasia.

M. Swift, M. Perry, C. Chase, 1976, Cancer research.

Eosinophilic meningitis in Hodgkin disease

M. Perry, R. Patchell, 1981, Neurology.

Skin Metastases in Non-small Cell Lung Cancer

M. Perry, R. Bobba, D. Doll, 2012, The American journal of the medical sciences.

Fibroma in a mute swan.

M. Perry, P. Chang, V. Jasty, 1969, Journal of the American Veterinary Medical Association.

ADDISON'S DISEASE, ADRENAL AUTOANTIBODIES AND COMPUTERIZED ADRENAL TOMOGRAPHY:

M. Perry, M. Croxson, R. Eason, 1983 .

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

C. Compton, D. Kerr, M. Bertagnolli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatotoxicity of chemotherapeutic and oncologic agents.

M. Perry, P. King, 1995, Gastroenterology clinics of North America.

American Society of Clinical Oncology educational book

Michael C. Perry, M. Perry, 2003 .

Small cell lung cancer: have we made any progress over the last 25 years?

Michael, J. Urbanic, James, 2007, The oncologist.

Familial erythrophagocytic lymphohistiocytosis.

M. Perry, T. Loy, A. Diaz-Arias, 1991, Seminars in oncology.

A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

J P Pignon, M. Tattersall, R. Souhami, 1992, The New England journal of medicine.

Spinal cord glioma following irradiation for Hodgkin's disease

M. Perry, G. Amromin, R. Abadir, 1980, Cancer.

Epidermal Growth Factor Receptor-Targeted Therapy for Pancreatic Cancer

M. Perry, C. Papageorgio, 2007, Cancer investigation.

Perry's The Chemotherapy Source Book , 5/e

M. Perry, Facp., 2012 .

Osteosarcoma--a complication of chemotherapy for Hodgkin's disease in children.

M. Perry, N. Hakami, C. Bourgeois, 1983, American journal of clinical oncology.

O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC)

Michael R. Green, R. Marks, K. Kelly, 2003 .

History of small-cell lung cancer.

M. Perry, S. Haddadin, 2011, Clinical lung cancer.

Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes?

M. Perry, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.

M. Perry, C. Belani, G. Mills, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.

J. Holland, J. Herndon, Mark R. Green, 2002, Journal of the National Cancer Institute.

Lung Cancer

M. Perry, I. Maghfoor, 1995, Cancer Treatment and Research.

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.

M. Vangel, R. Komaki, R. Marks, 2004, The Journal of thoracic and cardiovascular surgery.

Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer.

R. Gray, M. Vangel, R. Komaki, 2003, Lung cancer.

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

J. Holland, C. Desch, J. Herndon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

R. Gray, J. Schiller, A. Dowlati, 2005 .

Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

R. Gray, J. Schiller, A. Dowlati, 2005 .

Chemotherapy Versus Chemoimmunotherapy (CAF v CAFVP v CMF Each t MER) for Metastatic Carcinoma of the Breast: A CALGB Study

A. Korzun, R. Weiss, M. Perry, 1987 .

Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.

W. Wood, P. Schein, D. Budman, 1982, Cancer treatment reports.

Radiation-induced liver disease.

M. Perry, R. Khozouz, Syed Z. Huq, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry.

D. Berry, J. Klein, H. Parnes, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hematologic Effects of Heavy Metal Poisoning

M. Perry, Q. S. Ringenberg, D. Doll, 1988, Southern medical journal.

Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics

D. Kiang, B. Kennedy, A. Korzun, 1995, Cancer.

Cigarette smoking and adult leukemia. A meta-analysis.

R. Brownson, T. Novotny, M. Perry, 1993, Archives of internal medicine.

in Patients With Pancreatic and Gastric Cancer

J. Holland, S. Tross, A. Korzun, 1986 .

Rhabdomyosarcoma of the Head and Neck

M. Perry, N. Hakami, 1980, Ear, nose, & throat journal.

Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599

R. Gray, J. Schiller, David H. Johnson, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.

R. Hahn, C. Moertel, M. Perry, 1976, Cancer treatment reports.

Addison's disease, adrenal autoantibodies and computerised adrenal tomography.

M. Perry, M. Croxson, S. Somerfield, 1982, The New Zealand medical journal.

The clinical significance of Bence Jones proteinuria.

R. Kyle, M. Perry, 1975, Mayo Clinic proceedings.

Acute leukemia/lymphoma of plasmacytoid T-cell type.

C. Caldwell, M. Perry, T. Loy, 1990, American journal of clinical pathology.

Hypokalemia in Acute Myelogenous Leukemia

M. Perry, M. Farhangi, J. Bauer, 1983, Southern medical journal.

Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables

M. Perry, Q. S. Ringenberg, D. Doll, 1989, Cancer.

Bilateral non-Hodgkin's lymphoma of the breast mimicking mastitis.

M. Perry, B. Dawn, 1997, Southern medical journal (Birmingham, Ala. Print).

Chemotherapy, toxicity, and the clinician.

M. Perry, 1982, Seminars in oncology.

Original Article Plasma microRNAs as novel biomarkers for early detection of lung cancer

Yong Wang, L. Gu, D. Zheng, 2011 .

Cognitive and Psychological Factors Associated with Early Posttreatment Functional Outcomes in Breast Cancer Survivors

M. Perry, A. Yee, S. Reid-Arndt, 2009, Journal of psychosocial oncology.

Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.

C. Obasaju, H. Wakelee, M. Perry, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

182 – Approach to the Patient with Cancer

Michael C. Perry, M. Perry, 2012 .

Primary unruptured ovarian pregnancy.

M. Perry, R. S. Sheldon, W. Hummer, 1966, American Journal of Obstetrics and Gynecology.

Chronic myelocytic leukemia developing as a second cancer in a patient with chronic lymphocytic leukemia

M. Perry, A. Khojasteh, H. Taylor, 1981, CA: a cancer journal for clinicians.

Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3‐weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer

S. Ramalingam, M. Perry, C. Belani, 2008, Cancer.

Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.

S. Ramalingam, M. Perry, C. Belani, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Octreotide has no effect on advanced colon cancer.

J. P. Smith, M. Perry, D. Doll, 1994, Journal of clinical gastroenterology.

Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.

M. Perry, T. Hoffman, W. Volkert, 2006, Cancer biotherapy & radiopharmaceuticals.

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.

H. Wakelee, R. Komaki, R. Marks, 2005, Lung cancer.

Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy: A subset analysis of CALGB study 8081

W. Wood, A. Korzun, M. Perry, 1988, Cancer.

Chemotherapy for advanced pancreatic cancer. A comparison of 5‐fluorouracil, adriamycin, and mitomycin (fam) with 5‐fluorouracil, streptozotocin, and mitomycin (fsm)

L. Panasci, M. Perry, R Gray, 1986, Cancer.

Phase I/II Trial of Etoposide and Carboplatin in Extensive Small‐Cell Lung Cancer: A Report from the Cancer and Leukemia Group B

Mark R. Green, S. Luikart, K. Propert, 1993, American journal of clinical oncology.

Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutc Window

M. Perry, Michael C Perry, Vikas Malhotra, 2003, Cancer biology & therapy.

Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer

M. Perry, S. Reid-Arndt, Catherine Hsieh, 2010, Psycho-oncology.

A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer

R. Govindan, D. Morgensztern, M. Perry, 2008, Acta oncologica.

Unusual Ph1 translocation in a preleukemia

M. Perry, K. Michalski, J. Miles, 1982 .

Textbook of Lung Cancer

M. Perry, 2001 .

Meningeal Myeloma: A Case Report and Review of Literature

M. Perry, I. Maghfoor, 2000 .

Companion handbook to The chemotherapy source book

M. Perry, 1999 .

Anaplastic Large-Cell Lymphoma Presenting As an Endobronchial Polypoid Tumor

M. Perry, R. Khozouz, Syed Z. Huq, 2008 .

Hodgkin's disease: is staging laparotomy still necessary?

M. Perry, D. Doll, V. Dorr, 1995, Seminars in Oncology.

Introduction: The histiocytic syndromes

M. Perry, D. Komp, 1991 .

Cisplatin in patients with gastric cancer: a Cancer and Leukemia Group B phase II study.

P. Schein, R. Mick, M. Green, 1986, Cancer treatment reports.

O-093 Meta-analysis of weekly paclitaxel as maintenance therapy foradvanced non-small cell lung cancer (NSCLC) patients following intitial chemotherapy

S. Ramalingam, M. Perry, C. Belani, 2005 .

Updated analysis of a phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC) CALGB 9734

Michael R. Green, E. Vokes, M. Perry, 2005 .

Phase II multicenter randomized trial of induction weekly paclitaxel (P) administered in combination with carboplatin (C) followed by weekly maintenance P vs. observation for patients (pts.) with advanced & metastatic non-small cell lung cancer (NSCLC)

M. Perry, C. Belani, G. Mills, 2000 .

Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the cancer and leukemia group B

R. Schilsky, D. Faraggi, W. Wood, 1991, Cancer.

Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.

M. Perry, C. Anderson, A. Lyss, 2004, Clinical breast cancer.

CALGB Study 9431: A randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC)

Michael R. Green, J. Herndon, E. Vokes, 2000 .

The suprahepatic gallbladder. An unusual anatomical variant.

M. Perry, J. C. Peters, L. D. Youngwirth, 1983, Radiology.

Tumors of unknown origin in the bone marrow.

M. Perry, Q. S. Ringenberg, D. Doll, 1986, Archives of internal medicine.

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.

K. Propert, R. Dillman, S. Seagren, 1990, The New England journal of medicine.

Highlights from: 2nd International Lung Cancer Congress Kauai, Hawaii, July 18-21, 2001.

M. Fisher, M. Perry, K. Maung, 2001, Clinical lung cancer.

Treatment of Elderly Non–small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial

S. Ramalingam, M. Perry, C. Belani, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Leukemic iritis with hypopyon

M. Perry, P. Henry, R. Gruenewald, 1979, Cancer.

Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.

J. Herndon, E. Vokes, Mark R. Green, 2000, Lung cancer.

Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.

J. Holland, J. Herndon, T. Ahles, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.

J. Ware, K. Propert, W. Eaton, 1987, The New England journal of medicine.

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

S. Adak, R. Livingston, M. Perry, 2000, The New England journal of medicine.

Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.

D. Spiegelman, W. Eaton, M. Green, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer

G. Strauss, K. Propert, D. Budman, 1992, Cancer Chemotherapy and Pharmacology.

Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.

J. Herndon, Mark R. Green, W. Eaton, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

M. Socinski, J. Herndon, E. Vokes, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxicity: ten years later.

M. Perry, 1992, Seminars in oncology.

Scar carcinoma of the lung: a historical perspective.

M. Perry, T. Loy, R. Bobba, 2011, Clinical lung cancer.

Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer

F. de Marinis, M. Salzberg, J. Jassem, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

NEOADJUVANT CHEMORADIOTHERAPY WITH SPHINCTER-SPARING SURGERY FOR LOW LYING RECTAL CANCER

M. Bryer, D. Ota, B. Miedema, 1997 .

Chemotherapy Versus Chemoimmunotherapy (CAF v CAFVP v CMF Each t MER) for Metastatic Carcinoma of the Breast: A CALGB Study

A. Korzun, R. Weiss, M. Perry, 1987 .

397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)

K. Nackaerts, B. Hellerstedt, S. Gadgeel, 2010 .

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.